Core Insights - Allergan Aesthetics has conducted a global survey involving over 12,000 consumers, revealing a shift towards multimodal treatment plans and a preference for holistic, natural results in aesthetic treatments [1][2][13] - The findings will be presented at the Aesthetic and Anti-Aging Medicine World Congress (AMWC) 2026 in Monaco, showcasing the evolution of the AA Signature™ framework to meet changing patient expectations [1][3] Group 1: Evolving Patient Expectations - Patients are increasingly open to exploring treatment combinations and desire personalized, long-term aesthetic plans, with 62% finding multiple aesthetic treatments appealing and 59% likely to adopt a structured multi-treatment approach [3][5] - A significant 78% of consumers expressed that they would feel more satisfied with their aesthetic journey if they worked towards an agreed long-term plan with their practitioner [3] Group 2: New Educational Solutions - Allergan Aesthetics will introduce a new report titled "Layered Beauty: The New Aesthetic Mindset" at AMWC 2026, which emphasizes the importance of structured treatment frameworks and education for practitioners [3][10] - The AA Signature™ Skin360+ initiative is designed to address real-world consumer needs by integrating injectable treatments with energy-based devices, reflecting the company's commitment to evolving its portfolio [5][6] Group 3: Scientific Innovation and Events - The AMWC 2026 will feature live injection sessions and symposia focusing on multimodal approaches in aesthetic practice, highlighting the integration of science and education in delivering personalized outcomes [7][8][10] - Allergan Aesthetics will present 21 scientific e-posters that showcase its leadership in advancing multimodal approaches to aesthetics, reinforcing its commitment to innovation [8][10]

Core Insights - Allergan Aesthetics, a subsidiary of AbbVie, will present its AA Signature™ multimodal treatment approach at the Aesthetic Anti-Aging Medicine World Congress (AMWC) in Dubai from October 1 to October 3, 2025 [1][2]. Group 1: AA Signature™ Treatment Approach - The AA Signature™ approach utilizes Allergan Aesthetics' extensive product portfolio and is supported by educational resources for healthcare professionals, addressing evolving patient needs [2][3]. - This treatment has been successfully launched in over 25 countries in 2025, with plans for further expansion [2][3]. - The methodology focuses on various patient needs, including Lift Up, Distinct Definition, and improved skin quality [2]. Group 2: Aesthetic Trends and Patient Needs - There is a global trend towards a more natural and individualized aesthetic, which the AA Signature™ approach aims to fulfill [3]. - The approach is designed to empower healthcare professionals to create tailored treatment plans, enhancing patient relationships and retention [3]. Group 3: Symposiums and Expert Sessions - The Allergan Medical Institute will host a symposium on the AA Signature™ approach, featuring a live injection demonstration and discussions on addressing patient needs [4][5]. - A separate symposium will focus on mastering skin quality through a multimodal approach, highlighting the integration of various aesthetic modalities [5][6]. Group 4: Clinical Data and Research - A significant percentage (94%) of individuals express a desire to improve their facial skin quality, indicating a strong market demand for effective aesthetic solutions [6]. - The event will showcase new clinical data and research findings related to personalized aesthetics and skin quality, furthering Allergan Aesthetics' commitment to innovation [9].

Core Viewpoint - Allergan Aesthetics, a subsidiary of AbbVie, has launched the HA5® Hydra Collagen Hydrating Foaming Cleanser, which is designed to provide hydration and thorough cleansing for the skin, enhancing the effectiveness of subsequent skincare products [1][2]. Product Overview - The HA5® Hydra Collagen Hydrating Foaming Cleanser features the proprietary HA5® Hydra Collagen Complex, which includes five forms of hyaluronic acid and vegan hydra collagen, aimed at delivering instant hydration [1][2]. - The cleanser is formulated with 100% naturally derived amino acid-based surfactants and Pea Peptides, making it suitable for dry and sensitive skin [2]. - Clinical studies indicate that the cleanser can effectively remove makeup and impurities while boosting skin hydration by 30% when used with the HA5® Hydra Collagen Replenish + Restore Hydrator [2][3]. Market Positioning - Allergan Aesthetics emphasizes innovation in aesthetic medicine, positioning the HA5® line as a benchmark for advanced skin hydration solutions [2]. - The new cleanser is part of a broader portfolio that includes products from SkinMedica®, SKINVIVE by JUVÉDERM®, and DiamondGlow®, all aimed at providing superior hydration [2]. Expert Endorsement - Dr. Tiffany J. Libby, a board-certified dermatologist, endorses the product, highlighting its dual function of cleansing and hydrating while respecting the skin barrier [3]. Pricing and Availability - The HA5® Hydra Collagen Hydrating Foaming Cleanser is priced at $48 and is available for purchase on SkinMedica.com [3].

Core Insights - Allergan Aesthetics, a subsidiary of AbbVie, has announced the 2025 class of entrepreneurs participating in The Confidence Project, an initiative aimed at empowering women entrepreneurs and closing the Confidence Gap [1][4]. Group 1: The Confidence Project Overview - The Confidence Project is led by BOTOX® Cosmetic and focuses on accelerating business growth for selected entrepreneurs from various industries and backgrounds [3]. - Participants will engage in a Virtual Community Summit that emphasizes business development, camaraderie, and financial coaching [3]. - Following the summit, entrepreneurs will enter an intensive "Boostcamp" powered by Hello Alice, providing practical tools, mentorship, and education to help scale their businesses [3][6]. Group 2: Grant and Selection Process - After the Boostcamp, select entrepreneurs will participate in a Pitch Lab to present their business ideas to a grant selection committee [4]. - A total of 20 entrepreneurs will be awarded a $20,000 grant each from BOTOX® Cosmetic to support their business goals [4][6]. - The selection panel includes executives from Allergan Aesthetics and established entrepreneurs in the aesthetics industry [4]. Group 3: Community and Impact - The initiative aims to foster a supportive community for women entrepreneurs, highlighting the importance of collaboration in building successful businesses [5]. - The announcement of the 20 grant recipients is scheduled for October 2025 [5].

Core Insights - Allergan Aesthetics, an AbbVie company, is launching "The Confidence Project" to empower women entrepreneurs and close the Confidence Gap [1][4][5] - The program invites business owners to apply for grants and mentorship opportunities, with applications open until May 9, 2025 [1][5] Program Details - The Confidence Project aims to support 250 women entrepreneurs this year, providing them with access to an intensive "Boostcamp" program that includes skill-building, mentorship, and networking [4][5] - Participants will have the opportunity to pitch their businesses for a chance to receive one of 20 grants worth $20,000 each [4][5] Financial Commitment - Since 2023, BOTOX® Cosmetic has allocated $1 million in grant funding to over 40 founders [4] - The initiative is part of a broader goal to empower 50,000 entrepreneurs by 2030 [7] Partnerships - The program is in partnership with Hello Alice, an online platform that assists businesses in launching and growing [4][5] - The collaboration aims to foster long-term growth and leadership among women in business [5]

Core Viewpoint - AbbVie has submitted a Biologics License Application (BLA) to the FDA for TrenibotulinumtoxinE (TrenibotE), a first-in-class neurotoxin for treating moderate to severe glabellar lines, characterized by rapid onset and shorter duration of effect [2][4]. Group 1: Product Overview - TrenibotE is a first-in-class botulinum neurotoxin serotype E with a rapid onset of action as early as 8 hours post-administration and a shorter duration of effect lasting 2-3 weeks [1][4]. - If approved, TrenibotE will be the first neurotoxin of its kind available to patients, providing a new option in the aesthetic treatment landscape [1][3]. Group 2: Clinical Data - The BLA submission is supported by data from over 2,100 patients treated with TrenibotE in clinical trials, including two pivotal Phase 3 studies (M21-500 and M21-508) and a Phase 3 open-label safety study (M21-509) [4]. - All primary and secondary endpoints of the Phase 3 studies were met, demonstrating efficacy and safety comparable to placebo, with treatment-emergent adverse events similar to those observed in placebo groups [4]. Group 3: Market Implications - TrenibotE has the potential to transform the aesthetic toxin treatment landscape, particularly for new patients who may have concerns about looking unnatural with neurotoxin treatments [3][5]. - The introduction of TrenibotE may empower patients to explore aesthetic treatments with greater confidence, addressing barriers to initiating neurotoxin use [5].